Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO Trial of the AGO and GBG study groups - Untch, M; Fasching, PA; Konecny, GE (J Clin Oncol, 2011)
et al.